当前位置: 首页 >> 检索结果
81. Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study.
作者: Jinghua Wang.;Xiufang Kong.;Lili Ma.;Zhenqi Ding.;Huiyong Chen.;Rongyi Chen.;Xuejuan Jin.;Caizhong Chen.;Jiang Lin.;Lindi Jiang.
来源: Rheumatology (Oxford). 2024年63卷5期1359-1367页
This study aimed to compare the efficacy and safety of adalimumab (ADA) vs tocilizumab (TCZ) in patients with Takayasu arteritis (TAK).
82. A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis.
作者: Matthew C Baker.;Audra Horomanski.;Yiwen Wang.;Yuhan Liu.;Shima Parsafar.;Robert Fairchild.;Joshua J Mooney.;Rishi Raj.;Ronald Witteles.;Mark C Genovese.
来源: Rheumatology (Oxford). 2024年63卷5期1297-1304页
Effective steroid-sparing therapies for the treatment of sarcoidosis are lacking; IL-6 antagonists may reduce sarcoidosis disease activity. This study assessed the safety and efficacy of the IL-6 receptor antagonist, sarilumab, in subjects with glucocorticoid-dependent sarcoidosis.
83. The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
作者: Herbert S B Baraf.;Puja P Khanna.;Alan J Kivitz.;Vibeke Strand.;Hyon K Choi.;Robert Terkeltaub.;Nicola Dalbeth.;Wesley DeHaan.;Rehan Azeem.;Peter G Traber.;Robert T Keenan.
来源: Rheumatology (Oxford). 2024年63卷4期1058-1067页
Serum urate (SU) lowering with PEGylated uricases in gout can reduce flares and tophi. However, treatment-emergent anti-drug antibodies adversely affect safety and efficacy and the currently approved PEGylated uricase pegloticase requires twice-monthly infusions. Investigational SEL-212 therapy aims to promote uricase-specific tolerance via monthly sequential infusions of a proprietary rapamycin-containing nanoparticle (ImmTOR) and pegadricase.
84. Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial.
作者: Dong Xu.;Jianmin Fang.;Shangzhu Zhang.;Cibo Huang.;Chenghui Huang.;Li Qin.;Xiaomei Li.;Meiqing Chen.;Xiumei Liu.;Yi Liu.;Zhijun Li.;Jiankang Hu.;Chunde Bao.;Wei Wei.;Jing Tian.;Xinwang Duan.;Xiaofeng Zeng.
来源: Rheumatology (Oxford). 2024年63卷3期698-705页
To evaluate the efficacy and safety of telitacicept in adult patients with primary SS (pSS) in a phase II randomized double-blind placebo-controlled trial.
85. Belimumab treatment of adult idiopathic inflammatory myopathy.
作者: Galina Marder.;Tam Quach.;Priyal Chadha.;Preeya Nandkumar.;Jimmy Tsang.;Todd Levine.;Elena Schiopu.;Richard Furie.;Anne Davidson.;Sonali Narain.
来源: Rheumatology (Oxford). 2024年63卷3期742-750页
To evaluate belimumab addition to the standard of care in patents with refractory idiopathic inflammatory myopathy (IIM).
86. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.
作者: Yannick Allanore.;Dinesh Khanna.;Vanessa Smith.;Martin Aringer.;Anna-Maria Hoffmann-Vold.;Masataka Kuwana.;Peter A Merkel.;Christian Stock.;Steven Sambevski.;Christopher P Denton.; .
来源: Rheumatology (Oxford). 2024年63卷3期639-647页
To investigate the course of interstitial lung disease (ILD) and the effects of nintedanib in patients with limited cutaneous systemic sclerosis (lcSSc).
87. Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab.
作者: Leonardo Palazzo.;Julius Lindblom.;Nursen Cetrez.;Henri Ala.;Ioannis Parodis.
来源: Rheumatology (Oxford). 2024年63卷3期798-808页
To identify determinants of neuropsychiatric (NP) flares in patients with SLE treated for active SLE yet no ongoing severe NPSLE with non-biologic standard therapy plus belimumab or placebo.
88. Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials.
作者: Alvaro Gomez.;Sandra Jägerback.;Christopher Sjöwall.;Ioannis Parodis.
来源: Rheumatology (Oxford). 2024年63卷2期338-348页
To determine the effect of antimalarial agents (AMA) and different doses and pharmaceutical forms of belimumab on preventing renal flares in patients with SLE treated for extra-renal disease.
89. Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort.
作者: Abeer Ghuman.;Dinesh Khanna.;Celia J F Lin.;Daniel E Furst.;Ganesh Raghu.;Fernando J Martinez.;Mauro Zucchetto.;Suiyuan Huang.;Angus Jennings.;Svetlana I Nihtyanova.;Christopher P Denton.
来源: Rheumatology (Oxford). 2024年63卷2期472-481页
To explore prognostic and predictive markers of SSc-associated interstitial lung disease (SSc-ILD) outcomes in a phase 3 trial (focuSSced) and prognostic markers in a real-world cohort (SMART).
90. Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis.
作者: Jelena Vojinović.;Ivan Foeldvari.;Joke Dehoorne.;Violeta Panaviene.;Gordana Susic.;Gerd Horneff.;Valda Stanevicha.;Katarzyna Kobusinska.;Zbigniew Zuber.;Bogna Dobrzyniecka.;Jonathan Akikusa.;Tadej Avcin.;Cecilia Borlenghi.;Edmund Arthur.;Svitlana Y Tatulych.;Chuanbo Zang.;Vassilis Tsekouras.;Bonnie Vlahos.;Alberto Martini.;Nicolino Ruperto.
来源: Rheumatology (Oxford). 2024年63卷1期140-148页
CLIPPER2 was an 8-year, open-label extension of the phase 3b, 2-year CLIPPER study on the safety and efficacy of etanercept in patients with JIA, categorized as extended oligoarticular arthritis (eoJIA), enthesitis-related arthritis (ERA) or PsA.
91. The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate.
作者: Sorwe Mojtahed Poor.;Marina Henke.;Thomas Ulshöfer.;Michaela Köhm.;Frank Behrens.;Harald Burkhardt.;Susanne Schiffmann.
来源: Rheumatology (Oxford). 2023年62卷12期3993-3999页
We investigated the impact of concomitant MTX on ustekinumab (UST) levels and antidrug antibody (ADA) formation in PsA and evaluated consequences in pharmacodynamics and pharmacokinetics.
92. Cost-effectiveness of cognitive behavioural and personalized exercise interventions for reducing fatigue in inflammatory rheumatic diseases.
作者: Huey Yi Chong.;Paul McNamee.;Eva-Maria Bachmair.;Kathryn Martin.;Lorna Aucott.;Neeraj Dhaun.;Emma Dures.;Richard Emsley.;Stuart R Gray.;Elizabeth Kidd.;Vinod Kumar.;Karina Lovell.;Graeme MacLennan.;John Norrie.;Lorna Paul.;Jonathan Packham.;Stuart H Ralston.;Stefan Siebert.;Alison Wearden.;Gary Macfarlane.;Neil Basu.; .
来源: Rheumatology (Oxford). 2023年62卷12期3819-3827页
To estimate the cost-effectiveness of a cognitive behavioural approach (CBA) or a personalized exercise programme (PEP), alongside usual care (UC), in patients with inflammatory rheumatic diseases who report chronic, moderate to severe fatigue.
93. E-learning and practical performance in musculoskeletal ultrasound: a multicentre randomized study.
作者: Stine Maya Dreier Carstensen.;Søren Andreas Just.;Marie Velander.;Lars Konge.;Martin Slusarczyk Hubel.;Thiusius Rajeeth Savarimuthu.;Mogens Pfeiffer Jensen.;Mikkel Østergaard.;Lene Terslev.
来源: Rheumatology (Oxford). 2023年62卷11期3547-3554页
To examine the effect of pre-course e-learning on residents' practical performance in musculoskeletal ultrasound (MSUS).
94. Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK).
作者: Cindy L J Weinstein.;Paula Sliwinska-Stanczyk.;Tomas Hála.;Marina Stanislav.;Anjela Tzontcheva.;Ruji Yao.;Yuliya Berd.;Sean P Curtis.;George Philip.
来源: Rheumatology (Oxford). 2023年62卷11期3601-3609页
The GO-BACK study was designed to evaluate the efficacy and safety of golimumab (GLM) treatment withdrawal in adults with non-radiographic axial spondyloarthritis (nr-axSpA) who demonstrate inactive disease during a 10-month open-label (OL) GLM run-in.
95. A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren's syndrome.
作者: Darren Bentley.;Benjamin A Fisher.;Francesca Barone.;Fabrice A Kolb.;Gemma Attley.
来源: Rheumatology (Oxford). 2023年62卷11期3644-3653页
Primary SS (pSS) is a chronic autoimmune disorder characterized by mucosal dryness and systemic symptoms. We tested the effects of inhibition of cathepsin S using the potent and selective inhibitor RO5459072 on disease activity and symptoms of pSS.
96. Self-monitoring combined with patient-initiated care in RA patients with low disease activity: cost-effectiveness analysis of an RCT.
作者: Bart F Seppen.;Marjolein J E Greuter.;Jimmy Wiegel.;Marieke M Ter Wee.;Maarten Boers.;Michael T Nurmohamed.;Wouter H Bos.
来源: Rheumatology (Oxford). 2023年62卷10期3366-3372页
Self-monitoring and patient-initiated care (PIC) leads to fewer outpatient clinic visits in patients with established RA with low disease activity (LDA) while healthcare outcomes are similar. This study assesses the cost-effectiveness of PIC with self-monitoring.
97. A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS).
作者: Deborah J Griffiths-Jones.;Yvonne Sylvestre Garcia.;W David Ryder.;John D Pauling.;Frances Hall.;Peter Lanyon.;Smita Bhat.;Karen Douglas.;Harsha Gunawardena.;Mohammed Akil.;Marina Anderson.;Bridget Griffiths.;Francesco Del Galdo.;Hazem Youssef.;Rajan Madhok.;Barbara Arthurs.;Maya Buch.;Kim Fligelstone.;Mohammed Zubair.;Justin C Mason.;Christopher P Denton.;Ariane L Herrick.
来源: Rheumatology (Oxford). 2023年62卷9期3133-3138页
Although the painful and disabling features of early diffuse cutaneous SSc (dcSSc) have an inflammatory basis and could respond to corticosteroids, corticosteroids are a risk factor for scleroderma renal crisis. Whether or not they should be prescribed is therefore highly contentious. Our aim was to examine safety and efficacy of moderate-dose prednisolone in early dcSSc.
98. A multidisciplinary lifestyle program for rheumatoid arthritis: the 'Plants for Joints' randomized controlled trial.
作者: Wendy Walrabenstein.;Carlijn A Wagenaar.;Marike van der Leeden.;Franktien Turkstra.;Jos W R Twisk.;Maarten Boers.;Henriët van Middendorp.;Peter J M Weijs.;Dirkjan van Schaardenburg.
来源: Rheumatology (Oxford). 2023年62卷8期2683-2691页
To determine the effect of a multidisciplinary lifestyle program in patients with RA with low-moderate disease activity.
99. Prospective double-blind study on the value of musculoskeletal ultrasound by dermatologists as a screening instrument for psoriatic arthritis.
作者: Jakub Grobelski.;Dagmar Wilsmann-Theis.;Pantelis Karakostas.;Charlotte Behning.;Peter Brossart.;Valentin S Schäfer.
来源: Rheumatology (Oxford). 2023年62卷8期2724-2731页
This study evaluated musculoskeletal ultrasound (MSUS) use by dermatologists previously trained on a novel handheld, chip-based ultrasound device (HHUD) to screen for early PsA.
100. Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial.
作者: Arnaud Constantin.;Roberto Caporali.;Christopher J Edwards.;João Eurico Fonseca.;Florenzo Iannone.;Edward Keystone.;Hendrik Schulze-Koops.;Taek Kwon.;Seungmin Kim.;SangWook Yoon.;Dong-Hyeon Kim.;Gahee Park.;Dae Hyun Yoo.
来源: Rheumatology (Oxford). 2023年62卷8期2838-2844页
The primary endpoint of the pivotal phase III study of infliximab (IFX) s.c. demonstrated non-inferiority of s.c. to i.v. IFX, based on 28-joint DAS-CRP (DAS28-CRP) improvement at week (W) 22 (NCT03147248). This post-hoc analysis investigated whether numerical differences in efficacy outcomes at W30/54 were statistically significant, using conservative imputation methods.
|